A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Edward B MaldonadoW Kimryn RathmellGeoffrey I ShapiroNaoko TakebeJordi Rodon AhnertDevalingam MahalingamNikolaos A TrikalinosArash Rezazadeh KalebastyMamta ParikhScott A BoernerCelene BalidoGregor KringsTimothy F BurnsEmily K BergslandPamela N MunsterAlan AshworthPatricia M LoRussoRahul R AggarwalPublished in: Cancer research communications (2024)
Adavosertib failed to exhibit objective responses in SETD2-altered ccRCC and other solid tumor malignancies though prolonged stable disease was observed in a subset of pts. Combination approaches may yield greater depth of tumor response.